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Background: The genetic pathways of aggressive changes of bone tumors are still poorly understood. It is very
important to analyze DNA copy number alterations (DCNAs), to identify the molecular events in the step of
progression to the aggressive change of bone tissue.
Methods: Genome-wide array-based comparative genomic hybridization (array CGH) was used to investigate DCNAs
of 14 samples from 13 aggressive bone tumors, such as giant cell tumors (GCTs) and osteosarcoma (OS), etc.
Results: Primary aggressive bone tumors had copy number gains of 17.8±12.7% in the genome, and losses of 17.3
±11.4% in 287 target clones (threshold for each DCNA: ≦085, 1.15≦). Genetic unstable cases, which were defined by
the total DCNAs aberration ≧30%, were identified in 9 of 13 patients (3 of 7 GCTs and all malignant tumors). High-level
amplification of TGFβ2, CCND3, WI-6509, SHGC-5557, TCL1A, CREBBP, HIC1, THRA, AFM217YD10, LAMA3, RUNX1 and
D22S543, were commonly observed in aggressive bone tumors. On the other hand, NRAS, D2S447, RAF1, ROBO1, MYB,
MOS, FGFR2, HRAS, D13S319, D13S327, D18S552, YES1 and DCC, were commonly low. We compared genetic instability
between a primary OS and its metastatic site in Case #13. Metastatic lesion showed increased 9 DCNAs of remarkable
change (m/p ratio ≧1.3 folds), compared to a primary lesion. D1S214, D1S1635, EXT1, AFM137XA11, 8 M16/SP6, CCND2,
IGH, 282 M15/SP6, HIC1 and LAMA3, were overexpressed. We gave attention to HIC1 (17p13.3), which was common high
amplification in this series.
Conclusion: Our results may provide several entry points for the identification of candidate genes associated with
aggressive change of bone tumors. Especially, the locus 17p11-13 including HIC1 close to p53 was common high
amplification in this series and review of the literature.
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The development and progression of aggressive bone
tumor is a multi-step process. The acquisition of chromo-
somal abnormalities in tumor cells and a series of genetic
alterations occurring over the life-time of the tumor are
one of the central events in malignant transformation or
aggressive change. Multiple studies have identified the
prevalence and clinical significance of a various genetic
markers in primary bone tumors [1,2]. However, the ge-
netic pathways of aggressive changes of bone tumors are* Correspondence: kanamori@med.u-toyama.ac.jp
1Department of Human Science, University of Toyama, 2630 Sugitani,
Toyama city, Toyama 930-0194, Japan
2Department of Orthopaedic Surgery, University of Toyama, 2630 Sugitani,
Toyama city, Toyama 930-0194, Japan
© 2012 Kanamori et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orstill poorly understood. It is very important to analyze
DNA copy number alterations (DCNAs), to identify the
molecular events in the step of progression to the aggres-
sive change of bone tissue.
Metaphase comparative genomic hybridization (meta-
phase CGH) enabled us to detect DCNAs on whole chro-
mosomes [3,4]. But the resolution of metaphase CGH is
approximately 2 Mb for amplifications and 10 − 20 Mb for
deletions. Advances in mapping resolution using array-
based CGH (array CGH), have greatly improved resolving
power in comparison to metaphase CGH, and provide
more details regarding both the complexity and exact
location of genomic rearrangements leading to DCNAs
[5,6]. Thereafter, array CGH technologies for identifyingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of genes involved in tumors [3,4].
In this study, we investigated DCNAs of human
aggressive bone tumors using the technique of array
CGH. The quantitative measurement of DCNAs across
the genome may facilitate oncogene identification, and
might also be used for tumor classification.
Materials and methods
Tumor tissue specimens and DNA extraction
Fourteen bone tumor samples were collected from 13
patients with aggressive bone tumors and frozen until
use. Samples from 7 giant cell tumors (GCTs), 5 osteo-
sarcoma (OS) and 1 chondrosarcoma, were obtained
from the surgical- or biopsied specimens at the Univer-
sity Hospital of Toyama (Table 1). Patients consisted of
6 men and 7 women with an average age of 32.9 years
old (range, 7–65 years). No cases had been received the
chemotherapy before the sampling. This study protocol
was approved by the Institutional Review Board for
Human Use at the University Hospital of Toyama.
Tumor specimens were stored frozen at −80°C until
use. Genomic DNA was isolated from the tumor accor-
ding to standard procedures using proteinase K diges-
tion and phenol-chloroform extraction [7].
Hybridization and analysis of array CGH
Hybridization and analysis of array CGH were performed
according to the manufacture’s protocols (Vysis-Abbott
Japan Inc., Tokyo, JAPAN). The array CGH consisted of
287 clones containing important tumor suppressor andTable 1 Clinicopathologic data on the samples in genomic ar
Cases Age Gender* Diagnosis**
1 16 F GCT
2 16 F GCT
3 18 M GCT
4 21 M GCT
5 25 M GCT
6 41 F GCT
7 55 M GCT
8 47 F chondrosarcoma
9 7 F OS
10 41 M OS
11 58 F OS
12 65 F OS
13a 18 M OS (primary)
13b OS (metastasis)
*Gender; F: female, M: male.
**Diagnosis; GCT: giant cell tumor, OS: osteosarcoma.
***Follow-up; m: month, y: year.
****Recurrence: The number means operation times due to the recurrences.
*****NED: no evidence of disease, AWD: alive with disease, DOD: dead of disease.oncogene loci. Each tumor DNA sample was labeled and
hybridized to microarrays for CGH. One hundred nano-
gram of tumor DNA was labeled by random priming with
fluorolink cy3-dUTP (Perkin-Elmer Life Sciences, Inc.,
Boston, MA, USA), and normal reference DNA was
labeled in the same fashion with cy5-dUTP. Then, the
tumor and control DNAs were mixed with Cot-1 DNA
(Vysis-Abbott Japan Inc), precipitated, and re-suspended
in microarray hybridization buffer containing 50% forma-
mide. The hybridization solution was heated to 80°C for
10 min to denature the DNA, and then was incubated for
1 h at 37°C. Hybridization was performed for 72 h in a
moist chamber, followed by post-hybridization wash in 50%
formamide/2xSSC at 45°C. Slides were mounted in phos-
phate buffer containing 4', 6-diamidino- 2-phenylindole
(array DAPI solution). Fluorescence intensity images were
obtained from the hybridized microarray slides using
GenoSensor Reader System equipped with Array 300 Soft-
ware (Vysis-Abbott Japan Inc.) according to the manufac-
ture’s instructions. The total intensity and the intensity
ratio of the two dyes for each spot were automatically cal-
culated [7,8].Evaluation of array CGH
The diagnostic cut-off level representing gains and losses
of DCNAs was set to 1.15 (upper threshold) and 0.85
(lower threshold), respectively [7,8]. The p value is the
probability that the data value for an individual set of
target spots is part of the normal distribution. All ratios










4y metastasis (+) DOD
9 m metastasis (+) DOD
20y none NED
6 m metastasis (+) DOD
4 m metastasis (+) DOD
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Reader System.
We defined the three grades by the genomic imbalances
from the data of array CGH; genetically stable group
(genetic aberration <5%), intermediate group (5%≦genetic
aberration <30%), genetically unstable group (genetic aber-
ration ≧30%).
Statistical analysis
The results are expressed as the mean ± SD. We used
independent sample t-test for continuous variables and
chi square test for categorical variables in comparison. A
p value less than 0.05 was considered significant. All
statistics were calculated using StatMate III software
(Atoms Co., Tokyo, Japan).
Results
Overall array CGH results in aggressive bone tumors
Figure 1 shows a representative case, and a microarray
slide which was hybridized by array CGH technique.
DCNAs of primary tumors showed 17.8±12.7% in gains,
and 17.3±11.4% in losses of target 287 clones. The ave-
rage of the proportion of total genetic instability reached
the 38.6±22.8%. Genetic unstable cases which were
defined by the total DCNAs aberration (≧30%) wereFigure 1 A representative case and an array CGH slide (Case #7). a: Ra
showing GCT (H&E x200). c: A study of microarray CGH.identified in 9 of 13 patients (3 of 7 GCTs and all malig-
nant tumors). All malignant cases were genetically clas-
sified into the unstable group. We picked up major gene
names, which showed many gain cases or loss cases. An
overall array CGH results and gene names of common
genetic instability are listed in Figure 2.
High-level amplification of TGFβ2 (1q41), CCND3
(6p21), WI-6509 (11qtel), SHGC-5557 (12ptel), TCL1A
(14q32.1), CREBBP (16q13.3), HIC1 (17p13.3), THRA
(17q11.2), AFM217YD10 (17qtel), LAMA3 (18q11.2),
RUNX1 (21q22.3) and D22S543 (22q11), was commonly
observed in aggressive bone tumors. On the other hand,
NRAS (1p13.2), D2S447 (2qtel), ROBO1 (3p12-13), RAF1
(3p25), MYB (6q22-23), MOS (8q11), FGFR2 (10q26),
HRAS (11q11.5), D13S319 (13q14.2), D13S327 (13qtel),
YES1 (18p11), D18S552 (18ptel) and DCC (18q21.3)
were commonly low (Figure 2).
Clinical relevance in GCT
GCT is an aggressive bone tumor, but not malignant.
Seven GCT series were divided into three groups: 3
cases were genetically unstable group, and 3 cases were
stable group (Figure 3). One case (Case #7) belongs to
the intermediate group. Histologically, however, we
could not find the difference in each GCT case. Thediographs of GCT originated from sternum. b: Histological appearance
CS
Gene names Location 1 2 3 4 5 6 7 8 9 10 11 12 13a 13b gain cases loss cases
TGFβ 2 1q41 7 0
CCND3 6p21 8 0
WI-6509 11qtel 7 0
SHGC-5557 12ptel 8 0
TCL1A 14q32.1 8 0
CREBBP 16q13.3 7 0
HIC1 17p13.3 7 1
THRA 17q11.2 8 0
AFM217YD10 17qtel 7 0
LAMA3 18q11.2 7 1
RUNX1(AML1) 21q22.3 7 0
D22S543 22q11 7 1
NRAS 1p13.2 1 10
D2S447 2qtel 0 9
RAF1 3p25 0 7
D3S1274, ROBO1 3p12-13 0 8
MYB 6q22-23 0 7
MOS 8q11 0 7
FGFR2 10q26 0 9
HRAS 11q15.5 2 7
D13S319 13q14.2 0 8
D13S327 13qtel 0 7
D18S552 18ptel 0 8
YES1 18p11 0 7
DCC 18q21.3 0 7
0.3 27.5 21.6 25.8 1.4 0.0 0.0 25.4 34.5 23.7 17.1 31.0 22.6 30.7
1.4 21.6 16.0 26.8 2.8 0.0 18.1 12.5 30.0 18.1 19.9 39.4 17.8 26.1
1.7 49.1 37.6 52.6 4.2 0.0 18.1 37.9 64.5 41.8 37.0 70.4 40.4 56.8
Green and red squares represent decreases (Tumor DNA/Normal DNA ratio 0.85) and increases (Tumor DNA/Normal DNA ratio 1.15) of DCNAs, respecti
*Genetic gain/loss (%) are caliculated as a ratio of increase or decrease of DCNAs based on the data of 287 clones.




Tumor/ Cases Giant cell tumor osteosarcoma
Figure 2 Summary of DCNAs data detected by array CGH.
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11.8 years. Tumor recurrence was observed in all cases
of genetically unstable group. On the other hand, the re-
currence rate of stable group was low (33.3%). However,
there was no significance between two groups (chi-Figure 3 Representative genetic unstable group (a-d) and stable grou
(OS), c: Case #12 (OS), d: Case 4 (GCT), e: Case #2 (GCT), f: Case #5 (GCT).square test; p = 0.083), because the sample size was
small.
As many GCTs have some telomeric associations, we
have given an attention to these areas. In analyzed 73
clones of telomeric area, losses of D2S447 (2qtel), andp (e, f) in a study of microarray CGH. a: Case #9 (OS), b: Case #10
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mainly observed.
Primary vs. Metastatic OS
We compared the genetic instability of both primary
OS and a metastatic lymph node in Case #13. Briefly,
18-year-old man presented with the left shoulder mass.
Radiographs revealed an osteosclerotic lesion of the pro-
ximal humerus (Figure 4a). A chest radiogram and CT
scans showed multiple lung metastases. A small nodule
was palpable in the axillary region. We biopsied bone
tumor and removed a local swelling lymph node. Histo-
logic examination of the both samples showed osteoblastic
OS (Figure 4b). Chromosomal analysis by G-band showed
77–82 chromosomes with various complicated transloca-
tion from the primary tumor.
In this case, array CGH resulted in 22.6% gain of
DCNAs and 17.8% loss of primary tumor (genetic total in-
stability; 40.4%). Chromosomal instabilities of primary
tumor detected by array CGH, are figured out (Figure 4c).
However, a metastatic lymph node showed the gain of
30.7%, and the loss of 26.1% of DCNAs (genetic total in-
stability; 56.8%). Genetic aberrations of a metastatic lesion
were clearly increased (Figure 4d). We picked up detectedFigure 4 Genetic instability analyzed by array CGH in Case #13. Prima
(c), whereas a metastatic lymph node showed 57 DCNAs in 287 clones (d). Th
compared with a primary bone tumor. a: A radiogram of humerus showing th
showing atypical cells with osteoid formation. c: A study of microarray CGH (pDCNAs presenting with remarkable significant gains
(≧1.30) or losses (≦0.85) in a metastatic sample compared
to a primary sample (m/p ratio), and listed in Table 2.
Thirty-one DCNAs of 287 clones were gained. Of these,
12 DCNAs also showed high level amplification in the pri-
mary site.
It is important to assess the change of DCNAs between
a metastatic tumor and a primary tumor. Nine DCNAs
(m/p ratio ≧1.30 folds) showed remarkable enhancement,
compared to a primary lesion; D1S1635 (1p36.22), D1S214
(1p36.31), EXT1 (8q24.11-q24), AFM137XA11 (9p11.2),
CCND2 (12p13), 8M16SP6 (12ptel), IGH (14qtel), HIC1
(17p13.3) and LAMA3 (18q11.2), 282 M15/SP6 (17ptel).
On the other hand, loss of DCNAs (≦0.85) in a metastatic
sample, was only LLGL1 (m/p ratio = 0.81) and FLI
(TOP3A) (m/p ratio = 0.85). Both of these genes are
encoded on the location of 17p11.2-17p12. These DCNAs
showing remarkable enhancement or decreasing, may pro-
vide several entry points for the identification of candidate
genes associated with metastatic ability.
Discussion
Our present analysis indicated to 25 genes showing gen-
etic instability, as target genes of aggressive bone tumorsry bone tumors showed the genetic instability of 26 DCNAs of 287 clones
e genetic aberration of metastatic lymph node is relatively high
e osteosclerotic change by the osteosarcoma. b: Histological appearance
rimary tumor). d: A study of microarray CGH (metastatic tumor).
Table 2 Genetic instability between primary and metastatic tumor at Case #13
location Gene name metastasis (≧1.30) primary tumor m/p ratio
1p 1p36 CDC2L1(p58) 1.39 1.33 1.05
1p36.33 PPKCZ 1.52 1.24 1.23
1p36.33 TP73 1.48 1.58 0.94
1p36.31 D1S214 1.76 1.21 1.45*
1p36.22 D1S1635 1.88 1.33 1.41*
1p36.13 D1S199 1.51 1.22 1.24
1q 1q21 WI-5663 1.73 1.64 1.05
5p 5p13 DAB2 1.87 1.55 1.21
8q 8q24.11-q24 EXT1 1.44 1.03 1.40*
8q24-qter PTK2 1.51 1.31 1.15
8q tel SHGC-3110 1.40 1.29 1.09
8q tel U11829 1.35 1.16 1.16
9p 9p11.2 AFM137XA11 1.52 1.16 1.31*
12p 12p tel 8 M16/SP6 1.49 1.08 1.38*
12p tel SHGC-5557 1.52 1.34 1.13
12p13 CCND2 1.71 1.29 1.33*
12p13.1-p12 CDLN1B(p27) 1.53 1.25 1.22
14q 14q32.32 AKT1 1.68 1.51 1.11
14q tel IGH(D14S308) 1.51 1.16 1.30*
14q tel IGH(SHGC-36156) 1.39 1.14 1.22
17p 17p tel 282 M15/SP6 1.52 1.14 1.33*
17p13.3 HIC1 1.42 1.04 1.37*
17p13.1 TP53(p53) 1.40 1.19 1.18
17p12-17p11.2 LLGL1 1.67 2.06 0.81*
17p12-17p11.2 FLI, TOP3A 1.60 1.88 0.85*
18q 18q11.2 LAMA3 1.73 0.87 1.99*
20q 20q13.1-q13.2 PTPN1 1.46 1.43 1.02
20q13 TNFRSF6B(DCR3) 1.50 1.23 1.22
21q 21q22.3 RUNX1(AML1) 1.40 1.16 1.21
21q22 DYRK1A 1.37 1.13 1.21
21q tel PCNT2(KEN) 1.56 1.30 1.20
*m/p ratio: the ratio of DCNAs between the primary (p) and metastatic (m) tumor (≧1.30 or ≦0.85). No DCNAs of the loss (≦0.85) was detected in the metastasis.
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observed in 10 cases (76.9%) of 13. NRAS mutations
have detected prostate cancers before [9]. However,
there has been no report about the relationship between
bone tumors and NRAS.
The incidence of aggressive changes of bone tissue
is low. Similar to other solid tumors, malignant
changes are characterized by high propensity for me-
tastasis. Metaphase CGH studies have identified fre-
quent gains and amplifications at 1p21-32, 1q21-24,
5p13, 6p12, 8q23-24, 8cen-q13, 17p11.2-13, 19q, and
Xp21, and frequent losses at 6q16, 10p12-pter, and
10q22-q26 in OS [2,10-13]. Recent studies have also
reported that amplification at 17p11.2-ptel has beenfound in approximately 13-29% of high-grade OS
[11,14,15].
In our data, the most remarkable change in metastatic
tumor was occurred at increases (≧1.30) of D1S1635
(1p36.22), D1S214 (1p36.31), EXT1 (8q24.11-q24),
AFM137XA11 (9p11.2), CCND2 (12p13), 8 M16/SP6
(12ptel), IGH (D14S308), HIC1 (17p13.3), 282 M15/SP16
(17ptel), and LAMA3 (18q11.2). DCNAs of p53
(17p13.1) have also increased scarcely (1.19 → 1.40),
which have been suggested as an OS-related gene. As
Chen, et al. [16] suggested, HIC1 (hypermethylated in
cancer-1 located at 17p13.3) was frequent with p53
mutations in human OS. Their results indicated the
importance of genes altered only through epigenetic
Kanamori et al. Journal of Experimental & Clinical Cancer Research 2012, 31:100 Page 7 of 7
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genetically modified tumor suppressor genes. In our
study, HIC1 was also higher in the metastatic lesion than
the primary site (m/p ratio =1.37 in Table 2). Therefore,
we gave attention to the locus of 17p13 including HIC1
as a target gene.
Recent studies have reported that overexpression of
17p11-p12 have been linked p53 degradation [10,16-20].
In Case #13, the gain of LLGL1, FLI (TOP3A) at 17p11-
p12 have also detected. However, these two DCNAs
were decreased in a metastatic sample, compared with
primary tumor, which might be important in the step of
metastasis. These findings support that target genes
close to p53 (17p13.1), may contribute to OS tumorige-
nesis [17,18].
Thus, the present pilot study suggests that array CGH
could powerful means to detect genetic instability and
gene aberrations that are reflected to the progression
and outcome of primary aggressive bone tumors. HIC1
is increased at the both step of aggressive change and
metastatic process. HIC1 might play a role of bone
tumor progression and metastasis. We should pay atten-
tion the locus of 17p11-13 including HIC1, LLGL1, FLI
(TOP3A), as well as p53. Further detailed studies are
necessary to clarify genetic pathways of the aggressive
bone tumors.
Conclusion
Our results may provide several entry points for the iden-
tification of candidate genes associated with aggressive
change of bone tumors. Especially, the locus 17p11-13 in-
cluding HIC1 close to p53 was common high amplifica-
tion in this series and review of the literature.
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